Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHelios Underw Regulatory News (HUW)

Share Price Information for Helios Underw (HUW)

Share Price is delayed by 15 minutes
Get Live Data
211.50    1.00 (0.47%)
Bid:
210.00
Ask:
213.00
Spread: 3.00 (1.429%)
Market Cap: £145.34m
HUW Live PriceLast checked at - London Stock Exchange

Intraday Helios Underw Share Chart

Quarterly Syndicate Mid-point Forecast update

9 Apr 2026 07:00

RNS Number : 7165Z
Helios Underwriting Plc
09 April 2026
Β 

9 April 2026

Β 

Helios Underwriting plc

("Helios" or the "Company")

Quarterly Syndicate Mid-point Forecast update and announcement of new Share Repurchase Programme

Helios Underwriting, the only publicly traded company offering access to a diverse portfolio of syndicates at Lloyd's of London, the world's largest insurance market, todayΒ announces an updateΒ on the Q4 mid-point forecast for the 2023 and 2024 years of account (YOAs). The 2023 YOA profits, which are in line with expectations, will be realised in May 2026 and accordingly we are also announcing a share repurchase programme.

Louis Tucker, Chief Executive Officer, commented:

Β "The continued strong financial performance of Helios reflects the quality and diversification of our Lloyd's portfolio. The period has been characterised by an increasingly disciplined approach to the allocation of capital - prioritising established syndicates with profitable track records over new syndicates - while making headway in reducing our operational costs.

The launch of this share buyback programme demonstrates the strength of our conviction in the value of Helios. Backed by good visibility for the next two years of profit distributions from the prior YOAs."Β 

Quarterly Syndicate Mid-point Forecasts

The current mid-point forecasts in respect of its portfolio of syndicate capacity for the 2023 and 2024 YOAs based on the fourth quarter 2025 mid-point forecasts are:

Β 

2023

2024

2025

Β 

Β£m

Β£m

Β£m

Total capacity as at 31st Dec 2025

Β 

Retained

255.5

407.7

337.7

Reinsured / Third party

66.3

115.2

158.3

321.8

522.9

496.0

Mid-point forecast at 30th September 2025

16.1%

8.3%

Current mid-point at 31st December 2025

17.0%

9.3%

Changes in mid-point forecast

0.9%

1.0%

Syndicate Business Forecast (SBF)*

13.5%

Β *Return on capacity estimate for the Helios portfolio using data from the syndicate business plan. It is used as a reference as mid-point forecasts for 2025 YOA are not yet available.

Activity During the Period

The prior YOAs estimates continue to improve in line with expectations and are tracking towards a strong ultimate result. This demonstrates the underlying strength of pricing adequacy.Β 

The 2023 mid-point forecast improved to 17.0% (16.1% as at Q3 2025) in line with expectations, in the final quarter and these profits will be realised in May 2026.

The 2024 calendar year experienced above average levels of catastrophe losses with the majority of the California wildfire claims attributed to the 2024 year of account. We are starting to see the mid-point forecast gradually improving, by c1 percentage point, to 9.3% profit on capacity (8.3% as at Q3 2025), and the year is tracking towards a strong ultimate result.

Following changes in reporting by Lloyd's of London, the ultimate forecasts will be reported from the fifth quarter, which will be available from June 2026 for 2025 YOA. The 2025 calendar year so far has experienced below average levels of catastrophe losses, which is expected to be reflected in the forecasted profit for 2025 YOA.

Share Repurchase Programme

Helios announces that the Board of Directors has approved a share repurchase programme to return up to a maximum aggregate amount Β£2,000,000 to the Company's shareholders ("The Programme").

About the Programme

The following is a summary of the authority given to the company at the annual general meeting (AGM) on 30 June 2025:

Β· The aggregate number of ordinary shares of 10 pence each ("Ordinary Shares") acquired by the Company pursuant to this share purchase programmes shall not exceed the maximum number of Ordinary Shares which the Company is authorised to purchase pursuant to the authority obtained at the Company's AGM to repurchase up to a maximum 7,244,295 Ordinary Shares ("General Authority") that was approved at the 2025 AGM on 30 June 2025.

Β· In accordance with the General Authority, the maximum price paid per Ordinary Share acquired by the Company pursuant to the Programme is to be no more than:

oΒ  105% of the average middle market closing price of an Ordinary Share on AIM for the five business days preceding the date of purchase; and

oΒ  the higher of the price of the last independent trade and the highest current independent purchase bid for Ordinary Shares on the trading venue where the purchase is carried out

Β· The Programme will commence on the date of this announcement and will continue until the earlier of either the expiration of the General Authority or until the maximum pecuniary amount has been purchased under the Programme.

Β· The purchased Ordinary Shares will be held by the Company in treasury at the Company's discretion for later reissue or cancellation. Shares held in treasury are not entitled to dividends and have no voting rights at the Company's general meetings.

Β· Share repurchases will take place in open market transactions and may be made from time to time depending on market conditions, share price and trading volume. The maximum price paid per Ordinary Share will be no more than the net tangible asset value per share of the Company.

Β· The Company confirms that it currently has no unpublished inside information.

Β· The Programme will operate in accordance with and under the terms of the relevant General Authority, and within the regulatory limit on the quantity of Ordinary Shares the Company may purchase on a single day. The Programme will be conducted within the parameters of the Market Abuse Regulation 596/2014/EU and the delegated regulations made pursuant to it (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018).

Β· As at the date of this announcement, the Company's total issued share capital consisted of 75,216,173 Ordinary Shares, with one voting right per share. The Company holds 5,630,255 Ordinary Shares in treasury. Therefore, the total number of voting rights in the Company was 69,585,918.Β 

Β 

ENDS

For further information, please contact:

Β 

Helios Underwriting plc

Louis Tucker - Chief Executive Officer

+44 (0)203 965 6441

Β 

Adhiraj Maitra - Director of Finance and Operations

+44 (0)203 743 2114

Β 

Deutsche Numis (Nomad and Broker)

Duncan Monteith / Charles Farquhar

+44 (0)20 7601 6100

Β 

Β 

FTI Consulting

Ed Berry

+44 (0)7703 330 199

Β 

Christian HarteΒ 

+44 (0)7974 288 763

Β 

Β 

Β About Helios

Helios provides a limited liability direct investment into the Lloyd's insurance market and is quoted on the London Stock Exchange's AIM market (ticker: HUW). Helios trades within the Lloyd's insurance market writing approximately Β£467m of capacity for the 2026 year of account. The portfolio provides a good spread of business being concentrated in property & casualty insurance and reinsurance. For further information please visit www.huwplc.com.

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
MSCFVLLBQZLBBBX
Date   Source Headline
25th Jun 20267:00 amRNSNet Asset Value Update - Q1 2026
22nd Jun 20263:59 pmRNSResults of Annual General Meeting
22nd Jun 20269:00 amRNSTransaction in Own Shares
15th Jun 20269:00 amRNSTransaction in Own Shares
12th Jun 20267:00 amRNSScrip Dividend Reference Price
8th Jun 20267:00 amRNSTransaction in Own Shares
5th Jun 20264:05 pmRNSGrant of LTIP Award
5th Jun 20267:00 amRNSGrant of LTIP Awards
1st Jun 20267:00 amRNSTotal Voting Rights
1st Jun 20267:00 amRNSTransaction in Own Shares
27th May 20267:00 amRNSNotice of AGM
26th May 20267:00 amRNSTransaction in Own Shares
21st May 20267:00 amRNSFinal Results for the year ended 31 December 2025
18th May 20267:00 amRNSTransaction in Own Shares
14th May 20267:00 amRNSTR-1 announcement
11th May 20267:00 amRNSTransaction in Own Shares
5th May 20267:00 amRNSTransaction in Own Shares
1st May 20267:00 amRNSTotal Voting Rights
27th Apr 20267:00 amRNSTransaction in Own Shares
22nd Apr 20267:00 amRNSTR-1: Acquisition of Voting Rights
21st Apr 20267:00 amRNSChange of Nominated Adviser
20th Apr 20267:00 amRNSTransaction in Own Shares
14th Apr 20265:17 pmRNSHolding(s) in Company
10th Apr 20267:00 amRNSDirector/PDMR Shareholding
9th Apr 20267:00 amRNSQuarterly Syndicate Mid-point Forecast update
20th Jan 20267:00 amRNS2026 YOA Portfolio Update
9th Jan 20267:00 amRNSAppointment of Chief Underwriting Officer
4th Dec 20255:42 pmRNSGrant of LTIP Awards
2nd Dec 20257:00 amRNSNet Asset Value(s)
13th Nov 20251:32 pmRNSDirector/PDMR Shareholding
13th Nov 20251:30 pmRNSDirector/PDMR Shareholding
7th Nov 202510:10 amRNSHolding(s) in Company
6th Nov 20251:51 pmRNSDirector/PDMR Shareholding
5th Nov 20255:48 pmRNSTR1 - Change in breakdown of voting rights
30th Oct 20257:00 amRNSResult of Tender Offer
24th Oct 202512:20 pmRNSResults of General Meeting
21st Oct 20257:01 amRNSDirector Appointments
21st Oct 20257:00 amRNSCapital Markets Day
29th Sep 20257:01 amRNSProposed Tender Offer and Notice of GM
29th Sep 20257:00 amRNSHalf Year Results
19th Sep 20257:00 amRNSAppointment of Chief Executive Officer
1st Sep 20253:37 pmRNSDirector/PDMR Shareholding
29th Aug 202512:52 pmRNSPDMR Dealing
28th Aug 20252:16 pmRNSDirector/PDMR Shareholding
26th Aug 20257:00 amRNSQuarterly Syndicate Mid-point Forecasts
1st Aug 20257:00 amRNSTotal Voting Rights
31st Jul 202512:12 pmRNSTR-1: Notification of major holdings
18th Jul 20257:00 amRNSResults of Scrip Dividend Election
9th Jul 20259:45 amRNSResults of Scrip Dividend Election
30th Jun 20255:40 pmRNSAppointment of Executive Director

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.